Cancer immunotherapy

Cancer immunotherapy

  • CN 103,957,939 A
  • Filed: 09/19/2012
  • Published: 07/30/2014
  • Est. Priority Date: 09/19/2011
  • Status: Active Application
First Claim
Patent Images

1. a compositions, described compositions comprises:

  • The express cell factor, without cancerous cell multiplication capacity, complete;

    Anti-PD-1 antibody with people'"'"'s programmed death 1 (PD-1) specific binding;

    AndTLR (toll sample receptor) agonist;

    Wherein with the described full cancerous cell of described TLR agonist preparation.

View all claims

    Thank you for your feedback